Home › Companies › Cullinan Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Cullinan Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 16, 2026: 4 items on Cullinan Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 2 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Cullinan Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Cullinan Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Nadim Ahmed | 37,519,241 | -- | -- | 12,116,759 | 4,126,430 | 76% | Not verified | — |
| Elect Director: Stephen Webster | 36,963,086 | -- | -- | 12,672,914 | 4,126,430 | 74% | Not verified | — |
| 2. Ratification of Appointment of Independent Registered Accounting Firm | 53,722,477 | 36,815 | 3,138 | -- | 0 | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 48,536,734 | 1,092,209 | 7,057 | -- | 4,126,430 | 98% | Approved | — |
Source: Cullinan Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
Each item below shows how the 183 asset managers that disclosed a Cullinan Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Nadim Ahmed
Cullinan Therapeutics, Inc.’s own tally for this item (“Elect Director: Nadim Ahmed”): 37,519,241 for, 12,116,759 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 10,971,822 for, 803,936 withheld, 26,165 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,020,880 | 0 | 27 | 4,487 | For |
| T. Rowe Price | 1,612,529 | 0 | 0 | 0 | For |
| BlackRock | 1,600,638 | 0 | 0 | 0 | For |
| State Street | 1,411,681 | 0 | 0 | 3,403 | For |
| Fidelity | 1,270,315 | 0 | 0 | 0 | For |
| TIAA | 741,826 | 0 | 0 | 0 | For |
| Charles Schwab | 433,275 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 374,677 | Withhold |
| American Century | 0 | 0 | 0 | 146,920 | Withhold |
| JPMorgan | 135,439 | 0 | 0 | 0 | For |
| Equitable | 95,565 | 0 | 0 | 28,210 | Mixed |
| Invesco | 108,711 | 0 | 0 | 0 | For |
| Brighthouse | 56,617 | 0 | 0 | 20,994 | Mixed |
| Bridge Builder Trust | 75,506 | 0 | 0 | 0 | For |
| Northern Trust | 73,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,618 | 0 | 0 | 23,561 | Mixed |
| Tema ETF Trust | 63,636 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 43,350 | Withhold |
| ProShares | 0 | 0 | 0 | 40,398 | Withhold |
| Prudential/PGIM | 27,800 | 0 | 0 | 5,658 | Mixed |
| John Hancock | 15,200 | 0 | 13,865 | 0 | Mixed |
| Advisor Managed Portfolios | 28,255 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 26,506 | Withhold |
| Goldman Sachs | 23,480 | 0 | 0 | 0 | For |
| Global X | 23,211 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 5 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Stephen Webster
Cullinan Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephen Webster”): 36,963,086 for, 12,672,914 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 10,844,651 for, 879,312 withheld, 77,960 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,018,677 | 0 | 27 | 6,690 | For |
| T. Rowe Price | 1,612,529 | 0 | 0 | 0 | For |
| BlackRock | 1,600,638 | 0 | 0 | 0 | For |
| State Street | 1,411,681 | 0 | 0 | 3,403 | For |
| Fidelity | 1,270,315 | 0 | 0 | 0 | For |
| TIAA | 741,826 | 0 | 0 | 0 | For |
| Charles Schwab | 433,275 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 374,677 | Withhold |
| American Century | 0 | 0 | 0 | 146,920 | Withhold |
| JPMorgan | 135,439 | 0 | 0 | 0 | For |
| Equitable | 95,565 | 0 | 0 | 28,210 | Mixed |
| Invesco | 108,711 | 0 | 0 | 0 | For |
| Brighthouse | 56,617 | 0 | 0 | 20,994 | Mixed |
| Bridge Builder Trust | 23,711 | 0 | 51,795 | 0 | Mixed |
| Northern Trust | 0 | 0 | 0 | 73,173 | Withhold |
| Lincoln Financial | 48,618 | 0 | 0 | 23,561 | Mixed |
| Tema ETF Trust | 63,636 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 43,350 | Withhold |
| ProShares | 0 | 0 | 0 | 40,398 | Withhold |
| Prudential/PGIM | 27,800 | 0 | 0 | 5,658 | Mixed |
| John Hancock | 15,200 | 0 | 13,865 | 0 | Mixed |
| Advisor Managed Portfolios | 28,255 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 26,506 | Withhold |
| Goldman Sachs | 23,480 | 0 | 0 | 0 | For |
| Global X | 23,211 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Combines 6 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION.
Cullinan Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 48,536,734 for, 1,092,209 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three — Advisory Vote on Executive Compensation The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,025,393 | 1 | 0 | 0 | For |
| T. Rowe Price | 1,612,529 | 0 | 0 | 0 | For |
| BlackRock | 1,600,638 | 0 | 0 | 0 | For |
| State Street | 1,414,568 | 516 | 0 | 0 | For |
| Fidelity | 1,270,315 | 0 | 0 | 0 | For |
| TIAA | 741,826 | 0 | 0 | 0 | For |
| Charles Schwab | 433,275 | 0 | 0 | 0 | For |
| Dimensional | 374,677 | 0 | 0 | 0 | For |
| American Century | 0 | 146,920 | 0 | 0 | Against |
| JPMorgan | 135,439 | 0 | 0 | 0 | For |
| Equitable | 123,775 | 0 | 0 | 0 | For |
| Invesco | 0 | 108,711 | 0 | 0 | Against |
| Brighthouse | 77,611 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 23,711 | 51,795 | 0 | 0 | Mixed |
| Northern Trust | 73,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 72,179 | 0 | 0 | 0 | For |
| Tema ETF Trust | 63,636 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,350 | 0 | 0 | 0 | For |
| ProShares | 40,398 | 0 | 0 | 0 | For |
| Prudential/PGIM | 33,458 | 0 | 0 | 0 | For |
| John Hancock | 29,065 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 28,255 | 0 | 0 | 0 | For |
| MFS | 26,506 | 0 | 0 | 0 | For |
| Goldman Sachs | 23,480 | 0 | 0 | 0 | For |
| Global X | 23,211 | 0 | 0 | 0 | For |
Fund voting reports, all 50 managers: 11,493,980 for, 307,943 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 8,963,500 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 7,648,268 | 0 | 0 | 0 | For |
| BVF INC/IL | 4,362,044 | 0 | 0 | 0 | For |
| State Street | 2,460,716 | 2,617 | 0 | 0 | For |
| T. Rowe Price | 2,271,337 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 1,814,764 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 0 | 1,808,334 | Withhold |
| RTW INVESTMENTS, LP | 1,705,960 | 0 | 0 | 0 | For |
| BlackRock | 1,601,020 | 26,332 | 0 | 0 | For |
| Venrock Adviser, LLC | 1,379,965 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,354,723 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,193,410 | 0 | 0 | 0 | For |
| Nuveen | 755,775 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 600,000 | 0 | 0 | 0 | For |
| BOONE CAPITAL MANAGEMENT LLC | 491,400 | 0 | 0 | 0 | For |
| Charles Schwab | 433,569 | 0 | 0 | 0 | For |
| Vanguard | 406,181 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 386,169 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 361,684 | 0 | 0 | 0 | For |
| Invesco | 0 | 290,890 | 0 | 0 | Against |
| Point72 | 278,319 | 0 | 0 | 0 | For |
| Northern Trust | 243,966 | 2,618 | 0 | 0 | For |
| Two Sigma | 243,434 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 243,006 | 0 | 0 | 0 | For |
| AQR | 206,597 | 0 | 0 | 0 | For |
Institutional-manager reports, all 147 managers: 41,282,263 for, 737,564 against, 1,808,334 withheld, 193 abstained. Showing the 25 largest; see all in the interactive database.
99.9% Approved · of votes cast
Description as filed by funds: Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2026.
Cullinan Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 53,722,477 for, 36,815 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 11,801,867 for, 56 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,025,394 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,612,529 | 0 | 0 | 0 | For |
| BlackRock | 1,600,638 | 0 | 0 | 0 | For |
| State Street | 1,415,028 | 56 | 0 | 0 | For |
| Fidelity | 1,270,315 | 0 | 0 | 0 | For |
| TIAA | 741,826 | 0 | 0 | 0 | For |
| Charles Schwab | 433,275 | 0 | 0 | 0 | For |
| Dimensional | 374,677 | 0 | 0 | 0 | For |
| American Century | 146,920 | 0 | 0 | 0 | For |
| JPMorgan | 135,439 | 0 | 0 | 0 | For |
| Equitable | 123,775 | 0 | 0 | 0 | For |
| Invesco | 108,711 | 0 | 0 | 0 | For |
| Brighthouse | 77,611 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 75,506 | 0 | 0 | 0 | For |
| Northern Trust | 73,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 72,179 | 0 | 0 | 0 | For |
| Tema ETF Trust | 63,636 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 43,350 | 0 | 0 | 0 | For |
| ProShares | 40,398 | 0 | 0 | 0 | For |
| Prudential/PGIM | 33,458 | 0 | 0 | 0 | For |
| John Hancock | 29,065 | 0 | 0 | 0 | For |
| Advisor Managed Portfolios | 28,255 | 0 | 0 | 0 | For |
| MFS | 26,506 | 0 | 0 | 0 | For |
| Goldman Sachs | 23,480 | 0 | 0 | 0 | For |
| Global X | 23,211 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,451,380 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.92% |
| 2 | T. Rowe Price | 2.62% |
| 3 | BlackRock | 2.60% |
| 4 | State Street | 2.30% |
| 5 | Fidelity | 2.07% |
| 6 | TIAA | 1.21% |
| 7 | Charles Schwab | 0.71% |
| 8 | Dimensional | 0.61% |
| 9 | American Century | 0.24% |
| 10 | JPMorgan | 0.22% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Lynx1 Capital Management LP | 14.59% |
| 2 | MPM BioImpact LLC | 12.45% |
| 3 | BVF INC/IL | 7.10% |
| 4 | State Street | 4.01% |
| 5 | T. Rowe Price | 3.70% |
| 6 | Blue Owl Capital Holdings LP | 2.95% |
| 7 | Kynam Capital Management, LP | 2.94% |
| 8 | RTW INVESTMENTS, LP | 2.78% |
| 9 | BlackRock | 2.65% |
| 10 | Venrock Adviser, LLC | 2.25% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BVF PARTNERS L P/IL | 10.56% | 13G |
| BlackRock | 7.24% | 13F |
| Vanguard Group | 5.37% | 13F |
| State Street | 4.14% | 13F |
| T. Rowe Price | 3.30% | 13F |
| Geode Capital | 2.23% | 13F |
| Dimensional Fund Advisors | 1.47% | 13F |
| Point72 | 1.47% | 13F |
| Morgan Stanley | 1.25% | 13F |
| Two Sigma | 0.85% | 13F |
Percentages above are of 61,451,380 shares outstanding, as reported by Cullinan Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cullinan Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Cullinan Therapeutics, Inc.'s shareholder meeting held June 16, 2026, in the 2025-2026 proxy season, 183 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 905 separate fund positions. On the most widely held item on that ballot — PROPOSAL TO VOTE, ON AN ADVISORY BASIS, TO APPROVE OUR NAMED EXECUTIVE OFFICER COMPENSATION. — Cullinan Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cullinan Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Cullinan Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.